Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.84-3.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GLUE
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $14, GLUE's earnings are too small for P/E to mean much; on sales it trades at 49× p/s (4.3× the 11× p/s peer median, and 0.9× even its own history). At a normal multiple the price implies ~-31% near-term growth vs our ~68% forecast. That gap is an optionality premium a financial-multiple model can't price — our $20 fair value covers only the as-is business, low confidence. Analysts target $25–$40. Note: our $20 fair value sits below the entire analyst range ($25–$40). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price sits about 31% below a flat-multiple fair value, while analysts forecast about 68% growth — below our forecast. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $28.00 | — | — | Analyst | medium |
| Peer EV/Sales | 12M | $5.39 | 15.9 | 0.28 | TTM | medium |
| Peer P/S | 12M | $3.22 | 11.4 | 0.28 | TTM | medium |
| Peer EV/Sales | 3Y | $12.31 | 15.9 | 0.72 | Analyst | medium |
| Peer P/S |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
$25.00 – $40.00 (median $28.00) · 5 analysts · as of 2026-08-07
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
| 3Y |
| $8.17 |
| 11.4 |
| 0.72 |
| Analyst |
| medium |
| Peer EV/Sales | 5Y | $16.00 | 15.9 | 0.95 | Analyst | medium |
| Peer P/S | 5Y | $10.81 | 11.4 | 0.95 | Analyst | medium |